Allsec Technologies Announce Interim Dividend For FY 23-24
Allsec Declared an Interim Dividend at INR 30/- per equity share of face value of INR 10/- each for the financial year 2023-24.
The company has fixed the Record Date as Friday, November 10, 2023, for the purpose of payment of the Interim Dividend. The payment of the Interim Dividend will be made on or before November 21, 2023, or within 30 days from the date of declaration in compliance with the provisions of Companies Act, 2013. The Interim Dividend will be paid through electronic mode or by dividend warrants, as applicable.
Aditya Birla Sun Life AMC Limited Announces Financial Results for Q2 FY-2023-24
- Revenue from Operations grew by 8% year-on-year from Rs. 3,111 million to Rs 3,350 million
- Operating Profit grew by 5% year-on-year from Rs. 1,728 million to Rs. 1,811 million
- Mutual Fund QAAUM witnessed growth of 10% year-on-year to Rs. 3,109 billion
- Equity Mutual Fund QAAUM increased by 9% year-on-year to Rs. 1,302 billion and Equity Mix to overall Mutual Fund QAAUM at 42%
- Monthly SIP Flows was at Rs. 9.68 billion for the month of September 2023
Cipla USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York
USFDA Conducts Routine cGMP Inspection at InvaGen Pharmaceuticals’ Manufacturing Facility
The United States Food and Drug Administration (USFDA) recently conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility unit 1 and 2 of InvaGen Pharmaceuticals Inc., a wholly-owned subsidiary of the company. The facility is located in Hauppauge, Long Island, New York, USA, and the inspection took place from 16th October 2023 to 25th October 2023.
Asian Paints Announce Interim Dividend in FY 23-24
Company to Pay Interim Dividend of Rs. 5.15 per Equity Share for FY 2023-24
The company has declared a payment of interim dividend of Rs. 5.15 per equity share of the face value of Re. 1 each for the financial year ending 31st March 2024. The record date for determining the entitlement of shareholders for the interim dividend is Friday, 3rd November 2023. The dividend will be paid to the shareholders on or after Monday, 13th November 2023.
Westlife posts resilient Q2FY24 performance; Sales up by 7% YOY
1H FY24 – Highlights for the first half of the year
- H1FY24 Sales witnessed a growth of 11% YOY
- Encouraging 3% SSSG in 1H FY24 on a strong base of last year
- EBITDA grew 7% YoY in 1H FY24.
Q2 FY24 – Highlights for the second quarter
- Maintained growth on a high base with Q2 sales at Rs. 6.15 bn, up 7% YoY
- Avg. Sales Per Store in Trailing Twelve Months (TTM) increased by 7% YoY
- Cash PAT at Rs. 614 mn; Op. EBITDA at Rs. 997 mn, grew 1% YoY
- On-premises as well as Off-premises businesses grew by 7% YoY
TCS Collaborates with VIAVI to Develop O-RAN Test Solutions for 5G Products Launch
TCS Expands its 25-Year Partnership with VIAVI to Transform its Test Framework and Build a Platform Agonistic Solution to Test Interoperability with Large OEMs
TCS Collaborates with VIAVI to Accelerate Launch of 5G Innovations with O-RAN Test Solutions
(TCS) has partnered with VIAVI Solutions to co-create an end-to-end test framework solution for O-RAN (Open Radio Access Network) devices, enabling device manufacturers and others to launch 5G innovations faster. TCS developed an intuitive, platform-agnostic solution that simplifies testing operations and reimagines the user experience for field engineers, system testers, and technology partners. The future-ready scalable test solution helped VIAVI transform its service delivery, allowing customers to launch innovative new products more quickly while ensuring regulatory compliance. TCS has been a key collaborator in VIAVI’s growth and transformation, co-innovating across every new generation of technology.
Through their 25-year partnership, TCS and VIAVI co-innovated across every new generation of technology from 2G onwards, shaping the technology ecosystem. TCS has played a key role in VIAVI’s growth and transformation, collaborating across new product development, managing existing product portfolios, integrating new products from acquisitions, and reimagining critical business functions. More recently, TCS helped VIAVI develop a first-of-its-kind 5G Open RAN portfolio of test verification and assurance solutions such as TM500 O-RU Tester, TeraVM O-DU Tester, and an end-to-end Open RAN test product suite.
Asian Paints Appoints Soumitra Bhattacharya as Additional Independent Director for Five-Year Term
Asian Paints has announced that Mr. Soumitra Bhattacharya will be joining the company as an Additional and Independent Director for a term of five years, effective from 26th October 2023 to 25th October 2028. Mr. Bhattacharya brings with him extensive experience in the manufacturing and FMCG sectors, having previously served as the Managing Director of Bosch Limited, and he is a well-respected figure in the Indian corporate world. The appointment of Mr. Bhattacharya is expected to bring valuable insights and expertise to Asian Paints, further strengthening the company’s leadership team.
• Chartered Accountant, The Institute of Chartered Accountants of India
• Bachelor of Commerce, Accounting & Finance, Kanpur Vishwavidyalay, Kanpur, U.P.
Zen Technologies Limited Wins Ministry of Defence Order for Advanced Tank Training System
Zen Technologies Limited Secures ₹100 Cr Order from Ministry of Defence for State-of-the-Art Force-On-Force Tank Training System
Zen Technologies Limited is thrilled to announce that it has received a significant order from the Ministry of Defence, India, for its innovative Force-On-Force Tank training system. This order, valued at approximately ₹100 Cr (inclusive of taxes), will enable Tank Units and Sub-Units to train using their own equipment on real terrains under authentic conditions, without the need for live ammunition.
The system has been entirely developed, designed, and tested in-house by Zen, and after extensive trials, the Army has recognized its immense suitability for their training requirements. As this marks the company’s first order for the force-on-force tank training simulators, Zen anticipates a strong demand for this product in both domestic and international markets in the near future.
Venus Remedies Granted Market Authorization for Bleomycin 15,000 IU in the United Kingdom
- Obtaining market authorization for Bleomycin from MHRA is a momentous accomplishment for Venus Pharma GmbH.
- Venus Remedies holds a total of 15 Market Authorizations (MA) for Bleomycin products across the globe
Venus Remedies is excited to share that their German subsidiary, Venus Pharma GmbH, has obtained market authorization for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion in the United Kingdom. This accomplishment is a significant milestone for the pharmaceutical company as it expands its global reach and demonstrates its dedication to improving cancer care through cutting-edge solutions.